FDA advisory committee to consider dronedarone in March

Following fast on the heels of the publication of the ATHENA trial in the NEJM, the FDA has announced that it will hold a hearing of the Cardiovascular and Renal Drugs Advisory Committee on March 18 to consider “the proposed indication in patients with a history of, or current atrial fibrillation or atrial flutter, for the reduction of the risk of cardiovascular hospitalization or death.”
The ATHENA slide set is available on ClinicalTrialResults.Com.

Speak Your Mind